The invention discloses a method for detecting intratumoral heterogeneity of triple-negative breast cancer. The method solidifies tissue samples from different parts of the same patient on the same tissue chip, and then performs immunohistochemistry on the tissue chip. , immunofluorescence, fluorescence in situ hybridization and other detection. Effectively reduce the cost of experiments, save time and manpower, and also reduce errors caused by batch experiments, improve the consistency of experimental results, and achieve better quality control. This method uses multi-probe combined with fluorescence in situ hybridization technology to evaluate the intratumoral heterogeneity of triple-negative breast cancer, which reduces the dependence on expensive equipment and investment costs, and is easy to be widely promoted. The invention quantitatively detects intratumoral heterogeneity of triple-negative breast cancer, and provides a clear evaluation index for accurately predicting postoperative recurrence and metastasis risk of patients.